Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

72.57USD
22 Oct 2018
Change (% chg)

$0.22 (+0.30%)
Prev Close
$72.35
Open
$72.91
Day's High
$73.49
Day's Low
$71.86
Volume
3,250,000
Avg. Vol
2,710,333
52-wk High
$73.49
52-wk Low
$52.83

Latest Key Developments (Source: Significant Developments)

Bioline Rx Ltd - Presents Top-Line Results From Phase 2A Combat/Keynote-202 Study In Pancreatic Cancer At Esmo 2018 Congress
Friday, 19 Oct 2018 

Oct 19 (Reuters) - BioLine RX Ltd ::BIOLINE RX LTD - PRESENTS TOP-LINE RESULTS FROM PHASE 2A COMBAT/KEYNOTE-202 STUDY IN PANCREATIC CANCER AT ESMO 2018 CONGRESS.BIOLINE - BL-8040 IN COMBINATION WITH KEYTRUDA DEMONSTRATED ENCOURAGING DISEASE CONTROL, OVERALL SURVIVAL IN PATIENTS WITH METASTATIC PANCREATIC CANCER.BIOLINE RX LTD - TRIPLE COMBINATION EXPANSION COHORT (BL-8040 + KEYTRUDA (PEMBROLIZUMAB) + CHEMOTHERAPY) TO COMMENCE BY YEAR-END.BIOLINE RX LTD - RESULTS SUPPORT FURTHER DEVELOPMENT OF COMBINATION AND EXPANSION OF COLLABORATION.BIOLINE RX LTD - TREATMENT REGIMEN WAS SAFE AND WELL TOLERATED.  Full Article

Imaginab Announces Collaboration With Merck For Cd8 T Cell I/O Imaging Agent
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Merck & Co Inc ::IMAGINAB ANNOUNCES COLLABORATION WITH MERCK FOR CD8 T CELL I/O IMAGING AGENT.IMAGINAB - MERCK TO BUY CO'S NOVEL MINIBODY CD8 T CELL IMAGING AGENT FOR USE IN IMMUNO-ONCOLOGY CLINICAL TRIALS FOR MULTIPLE TYPES OF CANCERS.IMAGINAB - MERCK IS MAKING EQUITY INVESTMENT IN CO'S SERIES B FINANCING ROUND.  Full Article

Merck's HIV Therapy Meets Primary Efficacy Endpoint In Phase 3 Study
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Merck & Co Inc ::MERC'S HIV THERAPY DELSTRIGO (DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL FUMARATE) MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 DRIVE-SHIFT STUDY EVALUATING SWITCH TO DELSTRIGO FROM OTHER ANTIRETROVIRAL TREATMENT REGIMENS.MERCK - AT WEEK 24, PARTICIPANTS WHO SWITCHED TO DELSTRIGO ON DAY 1 SHOWED DECREASES IN FASTING LDL-CHOLESTEROL AND NON-HDL-CHOLESTEROL.  Full Article

Dragonfly Therapeutics Announces New Multi-Target Collaboration With Merck
Monday, 1 Oct 2018 

Oct 1 (Reuters) - DRAGONFLY THERAPEUTICS::DRAGONFLY THERAPEUTICS ANNOUNCES NEW MULTI-TARGET COLLABORATION WITH MERCK TO USE DRAGONFLY'S PROPRIETARY TRINKET™ PLATFORM TO DEVELOP NOVEL DRUG CANDIDATES FOR PATIENTS WITH SOLID TUMORS.DRAGONFLY THERAPEUTICS - MERCK RECEIVES EXCLUSIVE OPTIONS TO LICENSE NUMBER OF CO'S CANDIDATE NATURAL KILLER CELL ENGAGER IMMUNOTHERAPIES.  Full Article

Agenus Inc Entered Royalty Purchase Agreement With XOMA
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Agenus Inc ::AGENUS INC - ON SEPTEMBER 20, CO, UNIT ENTERED ROYALTY PURCHASE AGREEMENT WITH XOMA (US) LLC.AGENUS - XOMA PAID $15.0 MILLION FOR RIGHT TO GET 33% FUTURE ROYALTIES & 10% FUTURE MILESTONES CO ENTITLED TO GET FROM INCYTE, MERCK.AGENUS - DEAL WITH XOMA EXCLUDES NEXT MILESTONE CO EXPECTS TO GET FROM INCYTE IN Q4 2018.  Full Article

Eisai And Merck Announce China NMPA Approval Of Lenvima For Treatment Of Unresectable HCC
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Eisai Co Ltd <4523.T>::EISAI AND MERCK ANNOUNCE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVAL OF LENVIMA® (LENVATINIB) FOR TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC).MERCK & CO INC - APPROVAL WAS BASED ON RESULTS FROM REFLECT STUDY (STUDY 304), AN OPEN-LABEL, PHASE 3 TRIAL.  Full Article

Perrigo Expands Otc Growth Strategy With Rx-To-Otc Switch Licensing For Nasonex®
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Perrigo Company Plc ::PERRIGO EXPANDS OTC GROWTH STRATEGY WITH RX-TO-OTC SWITCH LICENSING FOR NASONEX®.FINANCIAL TERMS OF THE LICENSING AGREEMENT WERE NOT DISCLOSED.UNDER TERMS OF AGREEMENT, CO HOLDS RIGHTS TO MARKET, SELL, DISTRIBUTE A NON-PRESCRIPTION VERSION OF NASONEX(®) OTC IN THE UNITED STATES .AGREEMENT WITH SUBSIDIARY OF MERCK FOR EXCLUSIVE RIGHTS IN UNITED STATES TO PURSUE REGULATORY APPROVAL FOR NON-PRESCRIPTION, OTC NASONEX NASAL SPRAY.  Full Article

Express Scripts Announces New Recommendations "Tackling High Drug Prices"
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Express Scripts Holding Co ::SAYS ANNOUNCES NEW RECOMMENDATIONS "TACKLING HIGH DRUG PRICES".SAYS IN 2019, CO'S NATIONAL PREFERRED FORMULARY (NPF) TO PROVIDE ACCESS TO 3,886 MEDICATIONS.SAYS AMONG CHANGES TO NPF THAT TAKE EFFECT JAN. 1 ARE 48 NEW FORMULARY EXCLUSIONS.SAYS NEW FORMULARY EXCLUSIONS HAVE 22 DRUGS THAT HAVE LOW-COST GENERIC ALTERNATIVES.SAYS NEW FORMULARY EXCLUSIONS HAVE 12 INSTANCES OF COMPETITION WHERE DRUGS HAVE SAME ACTIVE INGREDIENT, BUT EXCLUDED DRUG HAS HIGHER NET COST.SAYS NEW FORMULARY EXCLUSIONS HAVE 11 SPECIALTY DRUGS THAT HAVE LOWER-COST BRAND OR BIOSIMILAR ALTERNATIVE WITH LOWER LIST PRICE.SAYS FOR TREATMENT OF HEPATITIS C, 2019 NPF WILL PREFER ZEPATIER AND HARVONI, EPCLUSA, AND VOSEVI IN PLACE OF MAVYRET.SAYS IN HIV CLASS, 2019 NPF WILL PREFER SYMFI AND SYMFI LO OVER ATRIPLA, WHICH WILL BE EXCLUDED.SAYS CHANGES IN 2019 NATIONAL PREFERRED FORMULARY WILL SAVE PLANS AN ESTIMATED $3.2 BILLION.SAYS ABOUT 0.2 PERCENT OF MEMBERS ENROLLED IN AN NPF PLAN WILL SEE A CHANGE IN 2019.  Full Article

Selumetinib Granted Orphan Designation In Europe For Neurofibromatosis Type 1
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Merck & Co Inc ::SELUMETINIB GRANTED ORPHAN DESIGNATION IN EUROPE FOR NEUROFIBROMATOSIS TYPE 1.MERCK - EMA GRANTED ORPHAN DESIGNATION TO SELUMETINIB, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1.  Full Article

Sutro Biopharma Announces $85.4 Million Series E Round
Thursday, 26 Jul 2018 

July 26 (Reuters) - Sutro Biopharma ::SUTRO BIOPHARMA ANNOUNCES $85.4 MILLION SERIES E ROUND.SUTRO BIOPHARMA - MERCK, KNOWN AS MSD OUTSIDE UNITED STATES AND CANADA, HAS MADE AN INVESTMENT AND HAS MADE A COMMITMENT TO A FUTURE INVESTMENT.SUTRO BIOPHARMA - FINANCING WAS LED BY SAMSARA BIOCAPITAL AND SURVEYOR CAPITAL & SUPPORTED BY ALTA PARTNERS, AMGEN VENTURES, CELGENE & OTHERS.  Full Article

Roche lands Tecentriq trial win, still trails Merck in lung cancer

ZURICH, Oct 22 Roche's Tecentriq plus chemotherapy boosted lung cancer patients' survival by nearly five months, study data released on Monday showed, underscoring benefits of the Swiss group's immunotherapy but still leaving it trailing a rival's drug.